But Douglas Cooper, executive director of the Nevada State Medical Board, said Wednesday the state panel has already taken some type of action in all 29 cases.
As a result of the Tuesday meeting with officials from Purdue Pharma, further review of some of the cases might be necessary but would remain confidential at this point in the process, he said.
“There were no surprises,” Cooper said. “The board is being very proactive in its drug investigations. We work more closely now than ever with law enforcement.”
You can read the full news story, at Las Vegas Review Journal.